Compare CIVB & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CIVB | DSGN |
|---|---|---|
| Founded | 1884 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 433.8M | 418.1M |
| IPO Year | N/A | 2021 |
| Metric | CIVB | DSGN |
|---|---|---|
| Price | $23.04 | $9.95 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $25.40 | $13.50 |
| AVG Volume (30 Days) | 72.0K | ★ 530.3K |
| Earning Date | 10-23-2025 | 11-05-2025 |
| Dividend Yield | ★ 2.95% | N/A |
| EPS Growth | ★ 33.31 | N/A |
| EPS | ★ 2.66 | N/A |
| Revenue | ★ $163,095,000.00 | N/A |
| Revenue This Year | $18.06 | N/A |
| Revenue Next Year | $11.12 | N/A |
| P/E Ratio | $8.66 | ★ N/A |
| Revenue Growth | ★ 11.28 | N/A |
| 52 Week Low | $17.47 | $2.60 |
| 52 Week High | $25.59 | $10.29 |
| Indicator | CIVB | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 65.92 | 71.98 |
| Support Level | $21.10 | $8.58 |
| Resistance Level | $23.44 | $9.85 |
| Average True Range (ATR) | 0.50 | 0.66 |
| MACD | 0.09 | 0.13 |
| Stochastic Oscillator | 85.22 | 86.62 |
Civista Bancshares Inc is a financial holding company. Operating through its subsidiary, it engages in the business of community banking. Its business activity involves collecting customer deposits, making loans, purchasing securities, and offering trust services to its clients. The company's loan portfolio includes commercial and agriculture, commercial real estate-owner occupied, commercial real estate non-owner occupied, residential real estate, real estate construction, and consumer loans. Majority of its revenues are derived from the interest and fees gained on loans.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.